FUJIREBIO US, INC.

Fujirebio US, Inc. specializes in the development and manufacturing of in vitro diagnostic substances, with a focused expertise in assay kits designed for use with luminescence-based analytical platforms such as the LUMIPULSE instrument. The company’s technical capabilities center on immunoassay reagent formulation, assay validation, and the production of clinical diagnostic kits that enable precise, high-sensitivity detection of biomarkers in clinical and research settings. Their work supports automated diagnostic systems requiring high reproducibility and regulatory compliance, positioning them as a niche supplier of critical reagents for laboratory-based infectious disease, oncology, and neurological testing applications. The precision and reliability of their diagnostic substrates suggest deep competency in bioconjugation chemistry, quality control for GMP environments, and lifecycle management of diagnostic kits under FDA oversight. The contractor maintains a consistent relationship with the Department of Health and Human Services, delivering diagnostic reagents and supporting administrative functions related to the obligational lifecycle of research contracts. This engagement reflects a trusted role in supplying materials critical to NIH-funded research initiatives and public health surveillance programs, indicating alignment with federal priorities in clinical diagnostics and translational science. Fujirebio US, Inc. operates within the in vitro diagnostic substance manufacturing sector (NAICS 325413), a specialized vertical focused on the production of biological reagents used in diagnostic testing platforms. The company’s market positioning is defined by its role as a supplier of proprietary assay components rather than end-user instruments, serving laboratories and research institutions requiring validated, scalable diagnostic solutions. As a 2L entity headquartered in Malvern, Pennsylvania, Fujirebio US, Inc. functions as a U.S.-based manufacturing arm supporting global diagnostic product lines. The company holds no active federal certifications, but its contract activity demonstrates sustained compliance with federal procurement and regulatory standards for diagnostic product supply. Its geographic presence is centered in the Philadelphia biotech corridor, aligning with regional strengths in life sciences and clinical diagnostics.